770 ADU-1604, a novel CTLA-4 blocking antibody modulates pharmacodynamic markers in PD1 relapse/refractory melanoma patients

• Caroline Robert,
• Ivan Marquez-Rodas,
• Michele Maio,
• Vanna Chiarion-Sileni,
• Piotr Rutkowski,
• Hans Van Eenennaam,
• Julien Villaudy,
• Jessica Kundapur,
• Ana Maria Arance,
• Alexander Eggermont,
• Guillemo De Velasco Oria de Rueda,
• Laura Lassouw-Polman

Affiliations

Caroline Robert

14 Paris-Saclay University, Gif-sur-Yvette, France

Ivan Marquez-Rodas

Aff3 0000 0001 0277 7938grid.410526.4Medical Oncology DepartmentHospital General Universitario Gregorio Marañón Madrid Spain

Michele Maio

Department of Oncology, University of Siena and Center for Immuno-Oncology, University Hospital, Siena, Italy

Vanna Chiarion-Sileni

11 Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

Piotr Rutkowski

Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute of Oncology Warsaw, Warszawa, Poland

Hans Van Eenennaam

1AIMM Therapeutics, Amsterdam, Netherlands

Julien Villaudy

J&S Preclinical Solutions, Oss, The Netherlands

Jessica Kundapur

2Kundapur Clinical Consulting, Nijmegen, The Netherlands

Ana Maria Arance

6Hospital Clínic Barcelona, Barcelona, Spain

Alexander Eggermont

Research Directorate Princess Maxima Center & Cancer Medicine University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

Guillemo De Velasco Oria de Rueda

1Colegio Oficial de Médicos de Madrid, Madrid, Madrid, Spain

Laura Lassouw-Polman

8Sairopa, Rotterdam, ZH, Netherlands